Pharmanutra H1 net result rises 8.1% to €9.9 million; sales revenues increase 17.9% to €73 million

• Pharmanutra net sales climbed 17.9% to EUR 73 million in the first half, lifted by international markets and flagship products.
• EBITDA rose 6.2% to EUR 17.5 million, while net profit attributable to shareholders increased 8.1% to EUR 9.9 million.
• Foreign-market net sales jumped 34.8% to EUR 28.2 million, raising their mix to 38.6% from 33.8% a year earlier.
• Net financial position swung to EUR -2.9 million from EUR 11.4 million at end-2025, mainly due to an EUR 11.5 million dividend.
• CEO Roberto Lacorte said new business units and Akern integration are starting to deliver, with second-half net sales expected to rise again.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharmanutra S.p.A. published the original content used to generate this news brief via SDIR, the Italian regulatory disclosure system (Ref. ID: 20106-27-2026_TELEBORSA.pdf), on September 11, 2026, and is solely responsible for the information contained therein.